Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallego-Pinazo, Roberto, Dolz-Marco, Rosa, Marín-Lambíes, Cristina, Díaz-Llopis, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619496/
https://www.ncbi.nlm.nih.gov/pubmed/23650454
http://dx.doi.org/10.4137/OED.S7264
Descripción
Sumario:Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.

Ejemplares similares